Physician Inducements: Bring On The Sunshine (Act) Say Indian Firms
Executive Summary
Indian pharmaceutical firms appear to have warmed up to the idea of making public their payments to doctors along the lines of those required under the Sunshine Act in the US. Physicians are also facing scrutiny in India over the unethical, so called “cut-practice”.
You may also be interested in...
India’s Generics-Only Rx Rule: Not What The Doctor Ordered Or What Pharma Wants?
New norms call for generics-only prescriptions and prohibits doctors from engaging in third-party educational activity backed by pharma in India. Will pharma need to rethink its branded generics strategy in India or is a tempering/deferment of the norms on the cards?
India Corporate Governance Practices – Will Pharma Walk The Gandhian Path?
As Sun Pharma firefights allegations of corporate governance lapses, Scrip speaks to multiple experts on how they view the governance landscape across Pharma Inc in India and also some key sticking points.
OPPI Chief Vaidheesh On Burning Industry Issues In India
The Organization of Pharmaceutical Producers of India (OPPI) essentially reflects the views of foreign firms in the country. In an interview with Scrip, OPPI’s new chief and GSK vice president (South Asia) and managing director (India) Annaswamy Vaidheesh shares the industry body’s take on several critical issues including the Indian government’s push for generic medicines and why the effective contract manufacturing model should not be “disrupted” by proposed policy reform.